MedPath

Topical Morphine for Analgesia in Patients With Skin Grafts

Phase 3
Withdrawn
Conditions
Pain
Skin Transplantation
Interventions
Registration Number
NCT00362219
Lead Sponsor
Rambam Health Care Campus
Brief Summary

The management of pain endured by patients after skin grafting is complex. Pain is the single most distressing symptom but as it is difficult to manage, it is often under-treated. These patients may experience pain from two types of wound: the original injury and from "skin-donor" sites, areas of healthy skin from which skin is surgically removed and used to cover the original injury. As the section of skin which is removed is standardized, the wound created at the donor site is uniform and so provides a model of an acute wound.

Opioids (such as morphine) are the backbone of treating the moderate to severe pain experienced by any patient. But due to their potentially severe side effects and that some patients do not experience sufficient relief from the treatment, optimal treatment schedules are still being sought after.

Topically applied morphine has provided effective and safe analgesia in several clinical models. We, therefore, wish to apply this treatment modality onto skin-graft donor wounds. If found to be effective this could be an appealing non-invasive method to treat the pain of this type of wound.

Detailed Description

Administration of morphine into the knee joint is the best-studied clinical procedure documenting the use of topically-applied opioids. When 1-5 mg morphine were injected into the knee joint, patients experienced pain relief for up to 24 hours, whereas similar doses given systemically (i.e. intravenously) were effective for 2-4 hours. Furthermore, the analgesic effect was reversed when the opioid antagonist naloxone was injected into the knee joint. Both these findings indicate that the effect is mediated by local opioid receptors in the knee joint.

Peripheral analgesic effects of opioids are not detectable in normal tissue but appear minutes to hours after initiation of inflammation. This suggests that opioid receptors are already present in the peripheral nerve terminals but under normal conditions they are not functional.

Research on application of opioids to skin wounds is very sparse and has primarily been performed in palliative care patients. These reports demonstrate that topical opioid gel (morphine or diamorphine) provided rapid and effective relief. In some patients pain subsided within 20 minutes after application with a long-lasting (7-8 hours) effect. Fundamental aspects regarding topical application of opioids onto skin wounds are still lacking. For example, issues such as optimal dose and dose-effect relationships have not been investigated. We hope to determine these in this study.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients undergoing skin-grafting
  • American Society of Anesthesiologists (ASA) classification I-II
  • Written consent
  • Either sex
  • Able to self-asses and report their pain level
Exclusion Criteria
  • Alcohol abuse or addiction - current
  • Opioids and benzodiazepines abuse - life time
  • Known hypersensitivity to morphine
  • Major renal or hepatic dysfunction
  • Pregnancy or lactation
  • Sleep-apnoea-syndrome
  • Diabetes
  • Participation in other clinical studies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboGel with no active ingredient
Morphine 1.25 mg.MorphineGel with 1.25 mg morphine per 100cm2 square of wound.
Morphine .25 mgMorphine - .25 mgGel with 0.25 mg morphine per 100cm2 square of wound
Morphine - .75 mg.MorphineGel with 0.75 mg morphine per 100cm2 square of wound.
Primary Outcome Measures
NameTimeMethod
Pain score in first 24 hours24 hours after application of the medication

Sum of the differences in pain scores between the skin-donor site vs. original injury site taken over a 24 hour period after application of the medication.

Secondary Outcome Measures
NameTimeMethod
Wound assessmentAverage day 12 post-operative

Assessment of the wound once the dressings are removed

Supplementary analgesic medicationsFirst 24 hours after surgery

Concurrent, supplementary, "rescue", analgesic medication (i.v.or oral morphine), given during the first 24 hours post operatively

Side effectsFirst 24 hours after surgery

Presence and severity of side effects: (a) central (nausea, vomiting, sedation, purities) and (b) local (burning, tingling, wheal, flare)

Analgesic medicine from 2nd post-operative day until dressings are removed.Day 2 post-surgery through 12th post-op day on average

Analgesic medication (type and dose), given from the second post-operative day until dressings are removed for the first time (= the 12th post-operataive day, on average).

Pain Score24 hours after surgery

Pain score at skin-donor site using an abbreviated form of the McGill Pain Questionnaire

Time course of analgesia for each drug concentrationFirst 24 hours after surgery

Time course of analgesia for each drug concentration

Pain score collectionTwice daily from day 2 post-op until day 8 post-op

Pain scores at donor and original injury, twice daily, from the second post-operative day until dressings are removed for the first time - up until 8th post-op day

Trial Locations

Locations (1)

Department of Plastic Surgery, Rambam Medical Center

🇮🇱

Haifa, Israel

© Copyright 2025. All Rights Reserved by MedPath